January 7, 2021
Ryvu Therapeutics to expand its Phase I study of SEL120 (RVU120) in patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome to Poland
Year
2021
Assets in this page
Download assets
- pdf file
Current Report ESPI 02/2021
Download